Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC
Indo US Bridging RARE Summit Highlights Patient Stories, Affordable Innovation, and Calls for Global Collaborations
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $74.00 price target on the stock.
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "outperform" rating re-affirmed by analysts at Robert W. Baird. They now have a $72.00 price target on the stock.